from three integrated firms (two firms in the Aegean region: 200 samples, one firm in the Black Sea region: 100 samples). Swab samples in Cary Blair transport medium was brought to the laboratory under cold chain. Each cloacal swab sample was inoculated on Levine agar plates supplemented with 2 µg/mL cefotaxime (Sigma, USA) and incubated for 24 h at 37 °C. One typical colony showing E.coli morphology per plate was selected and identified by conventional methods (Gram staining, morphology, catalase, oxidase, indole, urease, methyl red, VogesProskauer, and citrate) (5) and confirmed using a BBL Crystal Enteric/Nonfermenter ID Kit (Becton Dickinson, USA).
Antimicrobial susceptibility testing
Antimicrobial susceptibilities were determined using the Kirby-Bauer disk diffusion method on Mueller-Hinton agar (Merck, Germany), and the results were interpreted according to the Clinical Laboratory Standards Institute Guidelines (CLSI) (6) . E. coli isolates were tested for resistance agents. The 16 antimicrobial agents were ampicillin (AM, 10 µg), amoxicillin/clavulanic acid (AMC, 20 + 10 µg), ceftazidime (CAZ 30 µg), cefotaxime (CTX, 30 µg), cefoxitin (FOX, 30 µg), aztreonam (ATM, 30 µg), imipenem (IPM, 10 µg), gentamicin (GM, 10 µg), tobramycin (NN, 10 µg), amikacin (AN, 30 µg), streptomycin (S, 10 µg), tetracycline (TE, 30 µg), trimethoprim/sulfamethoxazole (SXT, 12.5 + 23.75 µg), nalidixic acid (NA, 30 µg), ciprofloxacin (CIP, 5 µg), and chloramphenicol (C, 30 µg). E. coli ATCC 25922 was used as an internal quality control strain for antimicrobial susceptibility testing.
ESBL phenotypic confirmatory tests
A ≥5 mm increase in the inhibition zone diameter for either cefotaxime/clavulanic acid or ceftazidime/clavulanic acid tested versus its zone when tested alone was considered as the phenotypic confirmation test for ESBL production (6).
Characterization of ESBL genes
Randomly choosing a colony from each cloacal sample, bla CTX-M (CTX-M groups 1, 8, 9, and 10), bla TEM, bla OXA-1, bla FOX, bla CMY, bla SHV , and ampC beta lactamase genes were studied using PCR (7, 8) . All obtained amplicons were sequenced on both strands, and sequences were compared with those included in the GenBank database and on the website http:/www.lahey.org/Studies/ to identify the betalactamase genes.
PFGE patterns of E. coli isolates producing ESBL
The clonal relationship between the strains was studied by PFGE, using XbaI as a restriction enzyme (9) . PFGE patterns were analyzed with BioMumerics software. The results were discussed according to the criteria given by Tenover et al. (10) .
Results
The results demonstrated that decreasing susceptibility for cefotaxime to E. coli isolates was detected in 101 of the 300 healthy broiler cloacal samples of our study, representing 33.6% of the total samples. A phenotypic confirmation test for detection of ESBL-producing isolates was carried out and 33 (11%) of all samples were determined to produce ESBL. Thirty-three phenotypic ESBL-producing E. coli isolates were further analyzed to examine the presence of beta-lactamase genes blaCTX-M (CTX-M groups 1, 8, 9, and 10), blaTEM, blaOXA-1, blaFOX, blaCMY, blaSHV, and ampC beta-lactamases and sequencing. Eight of the 33 E. coli isolates were designated as only harboring the bla TEM-1 gene. However, the bla CMY gene was not detected by PCR in these isolates. TEM-1, SHV-1, and OXA-type β-lactamases have been frequently described as broadspectrum β-lactamases. It was observed that 25 isolates had ESBL genes. The 25 ESBL-producing isolates were detected as 23 CTX-M (92%) (20 CTX-M-15, 1 CTX-M-1, 1 CTX-M-9, 1 CTX-M-16), 4 OXA-1 (16%), and 2 SHV-12 (8%) ( Table 1 ). 
The 25 ESBL-producing E. coli isolates were tested against 16 antimicrobial agents using the disk diffusion method. All isolates were determined to be resistant against multiple antibiotics (at least six antibioticresistant). The prevalence of antibiotic resistance of ESBL-positive E. coli isolates to ampicillin, amoxicillin/ clavulanic acid, cefotaxime, ceftazidime, aztreonam, gentamicin, amikacin, tobramycin, streptomycin, nalidixic acid, ciprofloxacin, trimethoprim/sulfamethoxazole, tetracycline, and chloramphenicol was 100% (n = 25), 56% (14) , 5% (13), 80% (20) , 40% (10), 76% (19), 4% (1), 56% (14) , 96% (24), 92% (23), 48% (12), 88% (22), 80% (20) , and 80% (20), respectively. All of the ESBL E. coli isolates were susceptible to cefoxitin and imipenem.
According to a similarity rate of 85% or over, 25 isolates was divided into two main groups, namely A and B, by PFGE analysis. Main group A contained A1 (6 isolates) and A2 (6 isolates), while main group B involved B1 (3 isolates) and B2 (10 isolates) (Figure; Table 1 ). The PFGE analysis illustrating the distribution of ESBL-producing E. coli is presented in Table 2 .
Discussion
This subject has gained importance due to the idiopathic increase in ESBL-producing E. coli prevalence among healthy farm animals, especially in poultry. ESBLproducing E. coli of poultry origin is a zoonotic risk factor for humans, as it could be directly or indirectly transmitted to humans and the environment by poultry breeding and products.
It has been reported that the prevalence of ESBLproducing E. coli in healthy broilers was 3.6% in Britain (11), 10.7% in France (12), 38.2% in Portugal (13), 45% in Belgium (1), and 60.8% in China (14) . There has been no research on antibiotic resistance phenotypes and genotyping characteristics of ESBL-carrying E. coli strains in healthy broilers in Turkey. In the present study, which was the first report in Turkey (25/300) about ESBLproducing E. coli prevalence among healthy broilers, it was detected as 8.3%. Differences in prevalence of ESBL-producing E. coli among various countries could result from antimicrobial use policies relating to poultry. In addition, the results reported by Dierikx et al. (15) demonstrated that the prevalence of ESBL-producing E. coli in the Netherlands varied between 0% and 100% in the poultry production pyramid during all stages: 0%-24% in 2-day-old chicks, 96%-100% in 18-week-old pullets, and 100% in 31-week-old hens. According to the results of that study (15) , there was no correlation between the increasing prevalence of ESBL-producing E. coli and the use of antimicrobial agents in poultry; this situation could occur by vertical-horizontal transmission.
ESBLs hydrolyze oxyimino-cephalosporins as cefotaxime and ceftazidime (16) . ESBL type CTX-M group are the most common currently, although SHV or TEM were common in the past (2) . The genes coding CTX-M group β-lactamase are harbored by plasmids as IS Ecp1. After determining the presence and transmitting by conjugation of ESBL type CTX-M groups in healthy foodproducing animals, this issue has become increasingly important (12, 17) .
The first ESBL-producing E. coli (CTX-M-14, SHV-12, and CMY-2) in poultry were isolated from healthy chick feces in Spain in 2000 and 2001 (7) . Recently published literature reported that the most common ESBL-type E. coli in healthy poultry were CTX-M-1 in France (12) CTX-M-65) and TEM in China (14) . In other studies, however, CTX-M-15 type ESBLs were reported as the most common: Panpan et al. (19) identified that the most common type of ESBL in China was the CTX-M-15 gene, while Maciuca et al. (20) conducted a study in poultry and people in Romania, reporting that the most common type in clinical isolates was also the CTX-M-15 gene.
Results from the present study, indicating that the highest prevalence for ESBL types was the CTX-M-15 gene, were consistent with the newly published research (19, 20) . This result was also similar to findings in the study on human medicine by Gür et al. (21) .
In conclusion, from broiler cloacal samples collected from slaughterhouses in Turkey, 8.3% ESBL-producing E. coli were isolated. These isolates had multiple antibiotic resistance. CTX-M-15 (80%) was the most frequently isolated ESBL type. Twenty-five isolates were divided into two main groups, namely A and B, by PFGE analysis. It was determined that these isolates had clonal similarity by PFGE analysis. 
